Other periodontal diseases Mental and behavioral disorders caused by the use of Tobacco
Conditions
Interventions
Group of 134 smoking patients enrolled in the Implant Dentistry Specialization Program at the Foundation of the School of Dentistry of the University of São Paulo (FFO-USP) who express a desire to qui
Sponsors
Faculdade de Odontologia da Universidade de São Paulo
Faculdade de Odontologia da Universidade de São Paulo
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Individuals who smoke and wish to quit. Partially edentulous patients who have at least one newly placed dental implant in the oral cavity, in a healed socket. Over 18 years of age. Both sexes
Exclusion criteria
Exclusion criteria: Completely edentulous patients. Immediate implants in fresh extraction sockets. Need for bone grafting in the implant area. Presence of any systemic alteration considered a risk factor for implant loss or failure (e.g., diabetes, HIV infection, etc.). Severe malocclusion (such as large transverse discrepancy of the jaws, etc.). Chronic use of non-steroidal or steroidal anti-inflammatory drugs. Use of bisphosphonates. History of radiotherapy in the head and neck region. Severe periodontal disease. Antibiotic therapy (prophylactic or not) in the last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the effect of smoking cessation on peri-implant marginal bone loss, measured with periapical radiographs. | — |
Secondary
| Measure | Time frame |
|---|---|
| Verify the difference between former smokers and current smokers in terms of probing depth in implants, obtained by performing a complete clinical exam of peri-implant tissues, after 3, 6,12, 24, 60 and 120 months.;Evaluate the occurrence of early implant failure, late implant failure, and incidence of peri-implantitis in smokers and former smokers.;Verify the impact of smoking cessation in oral health-related quality of life. Data was collected using the instrument OHIP-14.;Assess the effect of smoking cessation on saliva and peri-implant fluid on the levels of the following immune-inflammatory mediators after 3, 6, 12, 24, 60, and 120 months: Interferon-gama (INF-g), Interleukin-4 (IL-4), Interleukin-17 (IL-17), Interleukin-1 beta (IL-1b), Interleukin-10 (IL-10), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-a), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), Osteoprotegerin (OPG), Oxytocin (OC), Osteopontin (OPN), Receptor activator of nuclear factor kappa-? ligand (RANKL), Tumor Necrosis Factor-beta (TGF-b), tetrahydrogen triphosphate (CTP), and cotinine;Assess the smoking cessation rate at 12, 24, 60, and 120 months.;Evaluate the effect of smoking cessation on prosthetic outcomes. | — |
Countries
BR
Contacts
Public ContactCláudio Pannuti
Faculdade de Odontologia da Universidade de São Paulo
Outcome results
None listed